Antonio González-Martín

28PUBLICATIONS
158CO-AUTHORS
Molecular targetsOncology and carcinogenesis not elsewhere classifiedPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (28)

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

|Jul 02, 2025
Geneva Homologous Recombination Deficiency Test Is Predictive of Survival Benefit From Olaparib and Bevacizumab Maintenance in Ovarian Cancer.

Yann Christinat, Intidhar Labidi-Galy, Liza Ho

|Dec 05, 2024
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Hailei Zhang, Anna Rutkowska, Antonio González-Martín

|Oct 22, 2024
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.

Lucy Haggstrom, Yeh Chen Lee, Clare Scott

|Sep 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Antonio González-Martín, María Jesús Rubio, Florian Heitz

Pageof 5

Frequent Collaborators

8 joint publications

Bradley J Monk

5 joint publications

Kathleen Nadine Moore

5 joint publications

Ana Oaknin

5 joint publications

Isabelle Ray-Coquard